Loading
PRKCH (PRKCH upstream open reading frame 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.
Product of an upstream open reading frame (ORF) of PRKCH which regulates translation of the downstream protein kinase C eta (PKC-eta) ORF. Functions as a repressive element that maintains low basal levels of PKC-eta in growing cells but enhances its expression during stress conditions induced by amino acid starvation in a EIF2AK4/GCN2-dependent manner. In addition to its role in regulating PKC-eta translation, also inhibits the kinase activity of PKC-eta as well as other protein kinases including PRKCD, PRKCQ and PRKCE but not PRKCA, PRKCG or PRKCZ.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes clinical 0.92, affected pathway 0.76, literature 0.92, genetic association 0.07, animal model 0.42).
In plain words · PRKCH (PRKCH upstream open reading frame 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.
PRKCH (PRKCH upstream open reading frame 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.
Product of an upstream open reading frame (ORF) of PRKCH which regulates translation of the downstream protein kinase C eta (PKC-eta) ORF.
No product in this corpus aims at PRKCH yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PRKCH: RNA low tissue specificity; blood lineage group enriched (NK-cells 113 nTPM, T-cells 136 nTPM); high antibody staining in 19 normal tissues; highest cancer staining stomach cancer (2 of 8 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute myeloid leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PRKCH tissue; Open Targets ENSG00000027075 associations
First described 2003. Earliest sequence paper UniProt cites for the protein: Heilig et al, Nature, 2003, "The DNA sequence and analysis of human chromosome 14". Source.
Sources: HGNC HGNC:9403 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt C0HM02 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000027075 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.56, myeloproliferative neoplasm 0.62, systemic mastocytosis 0.54, leukaemia 0.63 (GraphQL API, CC0))
Product of an upstream open reading frame (ORF) of PRKCH which regulates translation of the downstream protein kinase C eta (PKC-eta) ORF. Functions as a repressive element that maintains low basal levels of PKC-eta in growing cells but enhances its expression during stress conditions induced by amino acid starvation in a EIF2AK4/GCN2-dependent manner. In addition to its role in regulating PKC-eta translation, also inhibits the kinase activity of PKC-eta as well as other protein kinases including PRKCD, PRKCQ and PRKCE but not PRKCA, PRKCG or PRKCZ. Locus 14q23.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: group enriched (NK-cells 113 nTPM, T-cells 136 nTPM).
Medium: Adrenal gland, Bone marrow, Breast, Cerebellum, Cerebral cortex, Endometrium, Epididymis, Fallopian tube.
Medium only: breast cancer, cervical cancer, glioma, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PRKCH" OR ABSTRACT:"PRKCH" OR TITLE:"protein kinase C eta" OR ABSTRACT:"protein kinase C eta" OR TITLE:"PRKCH upstream open reading frame 2" OR ABSTRACT:"PRKCH upstream open reading frame 2" OR TITLE:"PKC-L" OR ABSTRACT:"PKC-L" OR TITLE:"PRKCL" OR ABSTRACT:"PRKCL") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRKCH, not a curated reading list.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Systemic mastocytosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.